Peptides DB
Research-centric peptide and protocol reference hub

Research library

Every indexed study on every peptide in the database, with a machine summary and the numbers that matter pulled out. Filter on the left; the register updates as you go.

963studies indexed529with human data61registered trials809carry a numeric findingLibrarian added 24 studies today
Showing 7 studiesSortNewest indexed
B
grade
Expanded Hemodialysis Using a Medium Cut-Off Dialyzer for Severe Valproic Acid Poisoning: A Case Report with Real-Time Therapeutic Drug Monitoring.
L-Carnitine (Levocarnitine) · europepmc · 2023 · Case report · n=1
This case suggests that intermittent hemodialysis with a medium cut-off dialyzer can effectively reduce valproic acid levels in severe poisoning cases, but further studies are needed to confirm these findings.
VPA decreased to 97.81 µg/mL at 4 h (62.8% reduction).
A
grade
First-in-human nuclease-free homologous recombination-dependent gene editing in pediatric patients with methylmalonic acidemia: results of a phase 1/2 study.
L-Carnitine (Levocarnitine) · europepmc · 2026 · RCT · Phase 1
The SUNRISE study showed that while gene editing can increase MMUT expression, it did not effectively normalize serum methylmalonic acid levels, and safety concerns were raised due to treatment-emergent adverse events.
Not reported in abstract.
B
grade
Comparative Analysis of L-Carnitine and Coenzyme Q<sub>10</sub> Adverse Reaction Reports Using the EudraVigilance Database: Implications for Health and Sports Supplementation.
L-Carnitine (Levocarnitine) · europepmc · 2023 · Observational
L-carnitine and CoQ10 show different adverse reaction reporting patterns, with CoQ10 linked to a higher rate of serious cases. Caution is advised in interpreting these findings due to potential confounding factors.
34.2% serious cases for L-carnitine, 74.5% serious cases for CoQ10.
Showing 7 of 7